Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump

Gilead stock popped Monday after the biotech giant said it signed deals with three generic drugmakers to delay their Biktarvy copycats for two years.RBC Capital Markets analyst Brian Abrahams called the news a "solid win for GILD to extend their HIV life cycle."Biktarvy is, by far, Gilead Sciences (GILD) biggest moneymaker. The HIV treatment brought in $3.53 billion second-quarter sales. That accounted for more than 69% of the company's HIV sales.Under the deal, generic drugmakers Lupin, Laurus Labs and Cip ...